Clinical

Dataset Information

0

A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.

ABSTRACT: The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2007437 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers.
| S-EPMC9354395 | biostudies-literature
Unknown Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer.
| S-EPMC10175008 | biostudies-literature
Unknown S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
| S-EPMC4289339 | biostudies-literature
Clinical Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer
| 2038973 | ecrin-mdr-crc
Unknown Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
| S-EPMC3738125 | biostudies-literature
Unknown Case report: First case of pemetrexed plus cisplatin-induced immune hemolytic anemia in a patient with lung adenocarcinoma.
| S-EPMC9452692 | biostudies-literature
Unknown Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices.
| S-EPMC8080779 | biostudies-literature
Unknown Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer.
| S-EPMC5689692 | biostudies-literature
Unknown Feasibility Of Administering Adjuvant Chemotherapy Of Pemetrexed Followed By Pemetrexed/oxaliplatin Immediately Post-VATS In Patients With Completely Resected NSCLC.
| S-EPMC3256481 | biostudies-literature
Transcriptomics RNA-seq of A375 cells treated with I-BET726 alone and sequential combination of I-BET726 and Oxaliplatin
2025-12-22 | GSE306207 | GEO